Sotalol

SORBITOL · Sotalol (base and/or unspecified salts) · SOTALOL · Sotolol · dl-sotalol · Betacotdone · beta-Cardone · AURORA KA-855

https://huagongshe.com/de/chemical/5253

Identifikatoren & physikalische Daten

CAS No.	3930-20-9
Summenformel	C12H20N2O3S
Durchschnittliche Molmasse	272,37 g/mol
Monoisotopische Masse	272,1194635 g/mol
SMILES	CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1
InChIKey	ZBMZVLHSJCTVON-UHFFFAOYSA-N
PubChem CID	5253
ChEMBL	CHEMBL471
ChEBI	CHEBI:63622
EC No.	977-025-7
DTXSID	DTXSID0023589

Chemische & physikalische Eigenschaften

XLogP	0,2
Polarare Oberfläche (TPSA)	86,8
H-Brücken-Donoren	3
H-Brücken-Akzeptoren	5
Frei drehbare Bindungen	6
Schwere Atome	18
Formalladung	0
Komplexität	330
Arzneimittel	PharmaceuticalsPharmaceuticals -> Used in Switzerland
LogP (Verteilungskoeffizient)	1.10.53
Löslichkeit	7.82e-01 g/LChloroform (Slightly, Heated), Methanol (Slightly, Sonicated)
Human Drugs	Breast FeedingLactationMilk, HumanAntihypertensive AgentsAdrenergic Beta-AntagonistsAntiarrhythmicsPharmaceuticals
Schmelzpunkt	206.5 - 207 °C206.5-207 °C
Physical Description	Solid
Dissociation Constants	9.76
Collision Cross Section	167 Å² [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]
Siedepunkt	443.3±55.0 °C(Predicted)
Dichte	1.298 g/cm3
Lagerbedingungen	Hygroscopic, -20°C Freezer, Under inert atmosphere
Aggregatzustand	Solid
pKa (Säurekonstante)	pK1 8.2, pK2 9.8(at 25℃)
Farbe	Pale Yellow to Light Yellow
BCS Class	1
Stabilität	Hygroscopic
InChI	InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3
InChIKey	ZBMZVLHSJCTVON-UHFFFAOYSA-N
SMILES	CS(NC1=CC=C(C(O)CNC(C)C)C=C1)(=O)=O
CAS Datenbank	3930-20-9(CAS DataBase Reference)
NIST chemische Informationen	Methanesulfonanilide, 4'-(1-hydroxy-2-(isopropylamino)ethyl)-(3930-20-9)
EPA chemische Informationen	Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]- (3930-20-9)

Sicherheit & Vorschriften

GHS-Einstufung	DangerH315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]P203, P260, P263, P264, P264+P265, P270, P280, P302+P352, P305+P351+P338, P318, P319, P321, P332+P317, P337+P317, P362+P364, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Hazard Classes and Categories	Skin Irrit. 2 (100%)
Hepatotoxicity	Mild-to-moderate elevations in serum aminotransferase levels occur in less than 2% of patients on sotalol and are usually transient and asymptomatic, resolving even with continuation of therapy. Sotalol has been linked to a single case of clinically apparent liver injury, with onset of an acute hepatitis-like syndrome with prolonged jaundice 12 weeks after sotalol was initiated. The injury improved but did not resolve with discontinuation of sotalol. In large case series of drug induced liver disease and acute liver failure, sotalol has not been listed as a cause. Other beta-blockers have been linked to rare instances of acute clinically apparent liver injury with a latency to onset ranging from 4 to 24 weeks, a hepatocellular pattern of serum enzyme elevations and a mild, self-limiting course without evidence of hypersensitivity or autoimmune reactions.
Unerwünschte Wirkungen	Sotalol's adverse effect profile is inherent in the mechanisms of action as both a potassium channel blocker and a non-cardioselective β-blocker. The potassium channel blockade, primarily in phase 3 of the cardiac action potential, prolongs the QTc. Thus, the electrocardiogram (ECG) must be monitored upon initiating sotalol or adding other QTc-prolonging medications. Prolongation of the QT interval occurs in 1% to 2% of cases, which could lead to torsades de pointes or new ventricular tachycardia/ventricular fibrillation.
Toxizitätsübersicht	Sotalol toxicity is inherent due to the mechanism of action as both a potassium channel blocker and a non-cardioselective β-blocker and mirrors the adverse effect profile. The most obvious and potentially problematic sign of toxicity is concentration-related QTc prolongation. If QTc is over 500 ms during initiation, the sotalol dose should be reduced or discontinued. If QTc exceeds 520 ms during the maintenance phase of dosing, the clinician should either reduce the dose or discontinue sotalol.
Drug Induced Liver Injury	Drug-Induced Liver Injury Severity and Toxicity (DILIst)sotalolDILI NegativeOralDOI:10.1016/j.drudis.2019.09.022
Effects During Pregnancy and Lactation	◉ Summary of Use during Lactation
R-Sätze (R)	36/37/38
Gefahrensymbole	Xi
Sicherheitshinweise (S)	26-36